| Name: |
ABCIXIMAB (ReoproR) |
| Classification: |
platelet glycoprotein IIb/IIIa receptor antagonist (human monoclonal antibody)
- inhibits platelet aggregation
- used with heparin and aspirin as adjunct to percutaneous transluminal coronary angioplasty
|
| Dose: |
IV Direct:
- 0.25mg/kg over at least 1 minute given 10-60 minutes before the procedure
|
| Administration: |
IV Infusion:
9 mg / 250 ml sodium chloride 0.9%
- run at 10 ug/min for 12 hours post cardiac catheterization
- should be administered with a 0.2 micron filter
- requires dedicated line
|
Adverse Effects:
|
Hematological:
risk for complications increase in patients over 65 years, with history of GI disease or who weigh less than 75 kg
- major bleeding incidents (intracranial, GI or retroperitoneal characterized by abdominal, back or leg pain)
- thrombocytopenia
- anemia, leukocytosis
Cardiovascular:
- arrhythmias
- hypotension
- pericardial effusion, peripheral edema
Respiratory:
- pleural effusion, pericarditis
- pulmonary edema
- pulmonary embolism
- pneumonia
Other:
- nausea, vomiting
- visual distrubances
|
| Contraindications: |
- active hemorrhage
- active intracranial or gastrointestinal bleeding
- severe hypertension
- history of vasculitis
- underlying condition and risk for bleeding must be weight against potential benefits
|
| Caution: |
- readministration within 30 days is asoociated with more severe thrombocytopenia
|
| Monitoring Therapy: |
- INR/PTT
- hemoglobin
- platelet count
- bleeding
- continuous heart rate and ECG rhythm
- blood pressure
|
| Adult Critical Care Protocol: |
- May be administered IV direct or by IV infusion by an Adult Critical Care Nurse.
- Continuous infusions must be administered by infusion device and the pump library must be enabled.
|
